



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/562,256	06/28/2006	John Kim	00518-105029US1	3316
65989	7590	10/07/2010		
KING & SPALDING 1185 AVENUE OF THE AMERICAS NEW YORK, NY 10036-4003			EXAMINER SHAHNAN SHAH, KHATOL S	
			ART UNIT	PAPER NUMBER
			1645	
			NOTIFICATION DATE	DELIVERY MODE
			10/07/2010	ELECTRONIC

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

usptomailnyc@kslaw.com



**RESPONSE TO AMENDMENT**

1. The amendment filed 7/7/2010 has been entered into the record. Claims 1-10 and 14-15 have been cancelled. New claims 16-32 have been added. Claim 11 has been amended.

**Status of Claims**

2. Claims 11-13 and 16-32 are pending.

**Election/Restrictions**

3. Applicants have submitted new claims 16-32 in the amendment filed 7/7/2010. Claims 19 and 21-32 are drawn to non-elected species, since on election of 12/02/2008 for election of species applicants have elected *Streptococcus* group B. Therefore claims 19 and 21-32 are withdrawn from examination. Claims 11-13, 16-18 and 20 are under examination.

**Rejections Withdrawn**

4. Rejection of claims 11-13 under 35 U.S.C. 102 (b) made in paragraph 8 of the office action mailed 3/20/2009 is withdrawn in view of amendment filed 7/7/2010.
5. Rejection of claims 11-13 under 35 U.S.C. 102 (b) made in paragraph 9 of the office action mailed 3/20/2009 is withdrawn in view of amendment filed 7/7/2010.
6. Rejection of claims 11-13 under 35 U.S.C. 102 (b) made in paragraph 10 of the office action mailed 3/20/2009 is withdrawn in view of amendment filed 7/7/2010.
7. Rejection of claims 11-13 under 35 U.S.C. 102 (b) made in paragraph 11 of the office action mailed 3/20/2009 is withdrawn in view of amendment filed 7/7/2010.
8. Rejection of claims 11-13 under 35 U.S.C. 102 (b) made in paragraph 12 of the office action mailed 1/7/2010 is withdrawn in view of amendment filed 7/7/2010.
9. Rejection of claims 11-13 under 35 U.S.C. 103 (a) made in paragraph 14 of the office action mailed 1/7/2010 is withdrawn in view of amendment filed 7/7/2010.

**New Rejections Based on Amendment**

**Claim Rejections - 35 USC § 103**

10. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

Art Unit: 1645

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

The factual inquiries set forth in *Graham v. John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

**11.** Claims 11-13, 16-18 and 20 are rejected under 35 U.S.C. 103(a) as being unpatentable over Michon *et al.* US 6,602,508 B2 in view of WO 99/15671 both IDS of record.

The claims are drawn to a conjugate vaccine comprising an antigen that has been conjugated to tetanus toxin Fragment C, wherein said antigen is a capsular polysaccharide of *Streptococcus* group B and wherein the Fragment C does not exist in the conjugate vaccine as part of a whole tetanus toxoid molecule, and wherein the conjugate vaccine does not increase a patient's anti-tetanus titer response.

Michon *et al.* teach multivalent GBS conjugate vaccines comprising the multivalent conjugates, wherein different types of GBS capsular polysaccharides including types I, II, III, IV and V are conjugated to a single protein, such as tetanus toxin (see abstract, claims, and columns 3 and 9). Michon *et al.* do not explicitly teach Fragment C, however, this deficiency has been overcome by the teachings of WO 99/15671

Art Unit: 1645

WO 99/15671. teach a polypeptide comprising tetanus toxin fragment C or a fragment thereof and conjugate vaccine wherein the Fragment C does not exist in the conjugate vaccine as part of a whole tetanus toxoid molecule, and wherein the conjugate vaccine does not increase a patient's anti-tetanus titer response (see abstract, claims and figures). WO 99/15671 teach a 50 kD polypeptide as fragment C generated by papain digestion from tetanus toxin (see page 3 detailed description of invention). WO 99/15671 teach vaccine which comprises fragment C and may include other antigens to provide a multivalent conjugate vaccine (see page 1).

It would have been *prima facie* obvious to one of skill in the art to combine the teachings of Michon et al. and WO 99/15671 to obtain the claimed invention. One of skill in the art would have been motivated by the teachings of WO 99/15671 to use fragment C and conjugate it to a capsular polysaccharide of *Streptococcus* group B because WO 99/15671. teach vaccine which comprises fragment C and may include other antigens to provide a multivalent conjugate vaccine (see column 3, lines 20-24).

### **Conclusion**

**12.** No claims are allowed.

**13. THIS ACTION IS MADE FINAL.** Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP

Art Unit: 1645

§ 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Khatol S. Shahnan-Shah whose telephone number is (571)-272-0863. The examiner can normally be reached on Mon, Wed 12:30-6:30 pm, Thurs-Fri 12:30-4:30pm pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Larry R. Helms can be reached on (571)-2720832. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO

Application/Control Number: 10/562,256

Page 6

Art Unit: 1645

Customer Service Representative or access to the automated information system, call  
800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Khatol S Shahnan-Shah/

Examiner, Art Unit 1645

September 30, 2010

/Larry R. Helms/

Supervisory Patent Examiner, Art Unit 1645